Vivimed Labs Ltd

Vivimed Labs Ltd

₹ 4.95 -1.00%
31 Jul 2023
About

Vivimed Labs Ltd is primarily engaged in the business of APIs, CDMO, Finished Dosage Formulation, Specialty Chemicals and retail branded formulation manufacturing.[1]

Key Points

API Division (~69% of revenues)[1]
This is the flagship division of the company which is primarily managed by its subsidiary UQUIFA s.a. based in Spain. The division further has 2 sub-divisions :-[2]

  • Market Cap 41.0 Cr.
  • Current Price 4.95
  • High / Low /
  • Stock P/E
  • Book Value -0.66
  • Dividend Yield 0.00 %
  • ROCE -11.0 %
  • ROE -268 %
  • Face Value 2.00

Pros

Cons

  • Company has low interest coverage ratio.
  • The company has delivered a poor sales growth of -35.3% over past five years.
  • Promoter holding is low: 20.9%
  • Company has a low return on equity of -71.5% over last 3 years.
  • Contingent liabilities of Rs.123 Cr.
  • Company might be capitalizing the interest cost
  • Promoters have pledged 37.1% of their holding.
  • Company has high debtors of 203 days.
  • Promoter holding has decreased over last 3 years: -7.64%

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
38.99 65.26 54.38 56.52 61.13 50.11 44.22 55.74 37.03 35.35 33.64 41.46 38.62
55.33 54.47 64.85 63.81 62.21 58.69 53.53 60.87 201.32 35.68 39.54 40.19 67.09
Operating Profit -16.34 10.79 -10.47 -7.29 -1.08 -8.58 -9.31 -5.13 -164.29 -0.33 -5.90 1.27 -28.47
OPM % -41.91% 16.53% -19.25% -12.90% -1.77% -17.12% -21.05% -9.20% -443.67% -0.93% -17.54% 3.06% -73.72%
1.78 0.92 0.14 -0.36 0.57 0.08 0.15 0.05 0.68 0.11 2.20 0.04 7.63
Interest 9.21 9.51 8.62 11.58 10.06 9.31 8.85 9.22 8.52 10.66 11.89 13.21 -33.33
Depreciation 4.13 4.53 4.35 4.45 4.95 4.45 4.02 4.02 95.92 4.70 4.70 4.70 5.83
Profit before tax -27.90 -2.33 -23.30 -23.68 -15.52 -22.26 -22.03 -18.32 -268.05 -15.58 -20.29 -16.60 6.66
Tax % -1.58% 0.00% 0.00% 0.00% 18.17% -0.22% 0.00% 0.00% -0.77% 0.00% 0.00% -3.31% 20.87%
-27.46 -2.34 -23.30 -23.68 -18.33 -22.20 -22.03 -18.31 -265.99 -15.58 -20.30 -16.05 5.26
EPS in Rs -3.31 -0.28 -2.81 -2.86 -2.21 -2.68 -2.66 -2.21 -32.08 -1.88 -2.45 -1.94 0.63
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
1,109 1,351 1,380 1,346 1,462 1,186 1,315 1,059 861 237 187 149
916 1,139 1,156 1,111 1,057 971 1,135 1,049 830 245 374 182
Operating Profit 193 212 224 234 404 215 180 10 32 -8 -187 -33
OPM % 17% 16% 16% 17% 28% 18% 14% 1% 4% -3% -100% -22%
12 8 6 11 8 10 23 8 10 1 1 10
Interest 48 67 86 84 68 82 70 61 56 40 36 2
Depreciation 59 66 66 61 58 56 67 67 56 18 108 20
Profit before tax 98 87 78 100 286 86 66 -109 -70 -65 -331 -46
Tax % 15% 24% 7% 16% 25% 11% 13% -0% 3% 4% -1% -1%
84 66 72 84 214 76 57 -109 -72 -68 -329 -45
EPS in Rs 10.41 8.20 8.90 10.33 26.41 9.44 6.95 -13.16 -8.67 -8.16 -39.62 -5.48
Dividend Payout % 6% 7% 0% 0% 2% 4% 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: -20%
5 Years: -35%
3 Years: -44%
TTM: -20%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: 11%
TTM: 86%
Stock Price CAGR
10 Years: -23%
5 Years: -18%
3 Years: -39%
1 Year: %
Return on Equity
10 Years: -2%
5 Years: -38%
3 Years: -72%
Last Year: -268%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity Capital 16 16 16 16 16 17 17 17 17 17 17 17
Reserves 429 480 479 505 718 885 602 493 415 348 23 -22
729 958 1,076 1,015 1,011 1,149 1,280 1,268 326 359 379 377
402 404 327 519 317 343 431 432 532 543 651 579
Total Liabilities 1,577 1,858 1,898 2,055 2,062 2,394 2,329 2,210 1,289 1,266 1,069 951
709 808 813 814 879 1,035 965 1,045 502 520 436 418
CWIP 27 38 90 94 76 65 122 89 60 40 21 21
Investments 0 0 3 3 3 3 3 86 199 199 199 168
840 1,011 992 1,144 1,104 1,290 1,239 990 529 507 414 344
Total Assets 1,577 1,858 1,898 2,055 2,062 2,394 2,329 2,210 1,289 1,266 1,069 951

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
90 -118 140 154 58 21 422 80 567 28 35 -24
-170 -291 -107 -190 -68 -164 -89 -196 404 -16 -5 28
67 419 -42 41 35 186 -338 72 -1,015 -10 -34 -6
Net Cash Flow -12 11 -8 4 25 44 -5 -44 -44 1 -3 -2

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 101 94 87 88 50 85 99 86 46 134 150 203
Inventory Days 247 249 244 294 329 411 397 396 263 573 216 327
Days Payable 118 106 107 98 122 154 207 179 35 100 93 225
Cash Conversion Cycle 230 237 224 285 258 342 288 303 274 607 273 305
Working Capital Days 161 159 146 169 151 239 161 216 190 653 588 596
ROCE % 13% 12% 11% 12% 22% 9% 7% -3% -1% -3% -52% -11%

Shareholding Pattern

Numbers in percentages

Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024
28.57% 21.98% 20.96% 20.96% 20.96% 20.94% 20.94% 20.94% 20.94% 20.94% 20.94% 20.94%
1.64% 1.64% 1.64% 1.64% 1.64% 1.64% 1.64% 1.64% 1.64% 1.64% 1.64% 1.64%
0.12% 0.12% 0.12% 0.12% 0.12% 0.12% 0.12% 0.12% 0.12% 0.12% 0.12% 0.12%
69.67% 76.27% 77.29% 77.28% 77.29% 77.30% 77.30% 77.29% 77.30% 77.29% 77.30% 77.30%
No. of Shareholders 52,07453,11053,37652,39851,02650,68349,50349,03849,02749,01649,01249,003

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Concalls